Professional
Added to YB: 2025-07-03
Pitch date: 2025-06-30
THRD [neutral]
Third Harmonic Bio, Inc.
-0.92%
current return
Author Info
Clark Street Value is a special sits/event-driven investor. Sign up for the newsletter.
Company Info
Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases.
Market Cap
$242.8M
Pitch Price
$5.43
Price Target
N/A
Dividend
N/A
EV/EBITDA
0.41
P/E
-4.32
EV/Sales
N/A
Sector
Pharmaceuticals
Category
special_situation
Clark Street Value Mid Year 2025 Portfolio Review: Current Position - Third Harmonic Bio, Inc.
THRD (holding update): Biotech liquidating, returning $5.30-$5.44/share to shareholders with initial 90-95% distribution in Q3. Strategic alternatives announced just 2 months prior, unanimously approved. Doesn't include potential THB335 asset sale proceeds. Model for other broken biotechs to follow.
Read full article (1 min)